Log In
BCIQ
Print this Print this
 

Afinitor Disperz, everolimus

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionPediatric formulation of everolimus, an oral mTOR protein inhibitor
Molecular Target Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1)
Mechanism of ActionMammalian target of rapamycin (mTOR) kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBrain cancer
Indication DetailsTreat subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis (TS) in patients >=1 years of age for whom surgery is not a suitable option; Treat subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis (TS) in patients >=3 years of age for whom surgery is not a suitable option
Regulatory Designation U.S. - Accelerated Approval (Treat subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis (TS) in patients >=3 years of age for whom surgery is not a suitable option)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today